Loading... Please wait...
Contact Us
Would you like more
information on this report
Please contact us today at +44(0)20.7665.9240
or +1 212.220.0880
or write to us.

Breast Cancer: Update Bulletin [December 2016]

Product Code:
Publication Date:
December 2016

Gain new KOL insights on the latest events happening in Breast Cancer (BC). Pfizer announces the EU approval of Ibrance (palbociclib) for the treatment of women with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) locally advanced or metastatic BC; Novartis announces FDA priority review for the company's marketing application seeking approval of ribociclib (LEE011) as a first-line treatment for postmenopausal women with HR+/HER2-, advanced or metastatic BC in combination with letrozole; PharmaMar reports positive results of its Phase II study of lurbinectedin (PM1183) in patients with BRCA 1/2 –associated metastatic BC.

Highlights from this event update bulletin:

  • How do KOLs react to the EU approval of Ibrance (palbociclib)?
  • How is Ibrance likely to be used in the treatment paradigm?
  • According to KOLs, what are the chances of Ibrance being used as an adjuvant therapy in the future?
  • What do KOLs think of ribociclib and what challenges will it face?
  • What are KOL opinions of the Phase II data of lurbinectedin (PM1183) in patients with BRCA 1/2 – associated metastatic BC?
  • Where could lurbinectedin be positioned in the treatment algorithm?



All Contents Copyright © 2020 Doctor's Guide Publishing Limited All Rights Reserved